Recruiting soon

Immune Nutrition for Nutritional and Immune Support in Head and Neck Cancer Patients During Radiotherapy

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

IMPACT

Dietary Supplement
Who is being recruted

Head and Neck Neoplasms

+ Neoplasms

+ Neoplasms by Site

From 18 to 75 Years
+24 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Treatment Study

Interventional
Study Start: June 2025
See protocol details

Summary

Principal SponsorFirst Affiliated Hospital of Chongqing Medical University
Study ContactTao Zhang, MD
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: June 20, 2025

Actual date on which the first participant was enrolled.

This study focuses on improving the nutrition and immune system of patients with head and neck cancer during their radiotherapy treatment. Head and neck cancer can often lead to poor nutrition because of its location, and radiotherapy can make this problem worse. This can affect the success of the treatment. While guidelines suggest early nutritional support for these patients, there is no clear direction on what type of nutrition works best. Immunonutrition, which involves nutrients that help the immune system, has shown potential in reducing side effects from radiotherapy and improving immune response. This study aims to explore the benefits of immunonutrition on patients' nutrition, immune health, and overall quality of life during their radiotherapy. In this study, 48 patients with head and neck cancer who are about to start radiotherapy are given a special nutrition formula containing arginine, omega-3 fatty acids, and nucleotides. This formula is designed to support their immune system. Patients receive this formula along with guidance from dietitians and nurses throughout their treatment. The study measures the impact of this nutrition on radiotherapy side effects like mouth sores and swallowing difficulties, as well as changes in nutritional health, immune markers, and quality of life. These factors are assessed at different stages: before treatment, halfway through, and after completing radiotherapy. This approach helps to determine if immunonutrition can make a meaningful difference during cancer treatment.

Official TitleThe Impact of Immune Nutrition on Nutritional and Immune Status of Head and Neck Cancer Patients During Radiotherapy
NCT07017218
Principal SponsorFirst Affiliated Hospital of Chongqing Medical University
Study ContactTao Zhang, MD
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

48 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.



Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 18 to 75 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Head and Neck NeoplasmsNeoplasmsNeoplasms by Site

Criteria

14 inclusion criteria required to participate
Hematological and biochemical parameters within the following ranges:

White blood cell count (WBC) ≥3.5×10^9/L

Patients must be histologically or cytologically confirmed to have head and neck cancer (HNC).

Scheduled for radiotherapy with or without concurrent chemotherapy.

Show More Criteria

10 exclusion criteria prevent from participating
Prior history of radiation therapy or biological therapy targeting the head and neck region.

History of other malignant tumors in the past 5 years, except for adequately treated non-melanoma skin cancer or carcinoma in situ.

Severe systemic diseases, such as uncontrolled diabetes mellitus, severe cardiovascular disease, or chronic renal failure.

Pregnancy or lactation.

Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

One single intervention group is designated in this study

This study does not include a placebo group 

Treatment Groups

Group I

Experimental

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.
This study has no location dataSave this study to your profile to know when the location data is available.
Recruiting soonNo study centers